Drug Insights

Strategically Search Chlorthalidone on Synapse: A How-to Guide

21 March 2024
2 min read

Chlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys. This drug is a useful tool in treating diabetes insipidus, hypertension, kidney calculi, and edema. Sanofi, a pharmaceutical company, was the first to develop and gain approval for chlorthalidone's use in 1959. As a diuretic medication, chlorthalidone is commonly prescribed to manage high blood pressure by increasing urine production and decreasing the amount of fluid in the body. Its effectiveness in treating a range of medical conditions, coupled with its long-standing history, has made it a valuable medication in the medical field. Click on the image below to begin the exploration journey of Chlorthalidone through the Synapse database!

图形用户界面, 文本, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Formycon and Fresenius Kabi Reach Agreement on Ustekinumab Biosimilar FYB202 for European and Canadian Markets
Latest Hotspot
2 min read
Formycon and Fresenius Kabi Reach Agreement on Ustekinumab Biosimilar FYB202 for European and Canadian Markets
21 March 2024
Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)
21 March 2024
The article will discuss GPCR targets and noteworthy pipelines from Roche and TEVA at JPM Healthcare 2024.
Read →
Tunlametinib (HL-085): First Targeted Therapy for Advanced Melanoma with NRAS Mutation Approved Post PD-1/PD-L1 Treatment
Latest Hotspot
3 min read
Tunlametinib (HL-085): First Targeted Therapy for Advanced Melanoma with NRAS Mutation Approved Post PD-1/PD-L1 Treatment
21 March 2024
KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.
Read →
Harnessing Synapse for Colchicine Information: Strategies and Tips
Drug Insights
2 min read
Harnessing Synapse for Colchicine Information: Strategies and Tips
21 March 2024
Takeda Pharmaceutical's approval of colchicine in January 1995 marked a significant milestone in the world of medicine.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.